Liver tissue alterations in morbidly obese patients undergoing bariatric surgery

Experimental and Clinical Hepatology

Volumn 3, Issue 3, 2007, Pages 12-18

  Kukla, Michał ^a   Zwirska Korczala, Krystyna ^a   Gabriel, Andrzej ^a   Ziókowski, Adam ^a   Wylezoł, Mariusz ^a   Berdowska, Agnieszka ^a   Rybus Kalinowska, Barbara ^a   Kuka, Dorota ^a   Kalinowski, Mariusz ^a   Sosada, Krystyn ^a   Chwist, Alina ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Bariatric surgery; Liver fibrosis; Morbid obesity; Steatohepatitis; Steatosis

Indexed keywords

CHOLESTEROL; FIBRINOGEN;

ADULT; ARTICLE; BARIATRIC SURGERY; BILE DUCT INJURY; BODY MASS; CELL DEGENERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FATTY LIVER; FEMALE; FIBRINOGEN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; MALE; MORBID OBESITY; PORTAL VEIN; RATING SCALE;

EID: 36448997433     PISSN: 17343038     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bellentani S, Saccoccio G, Masutti F et al. Prevalence and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med, 2000; 132: 112-117.
2. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology, 2003; 124: 71-79.
3. Luyckx FH, Desaive C, Thiry A et al. Liver abnormalities in severely obese subjects: effects of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord, 1998; 22: 222-226.
4. Beymer C, Kowdley KV, Larson A, Edmonson P, Dellinger EP, Flum DR. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg, 2003; 138: 1240-124.
5. Clark JM. The epidemiology of non-alcoholic fatty liver disease in adults. J Clin Gastroenterol, 2006; 40, Suppl 1: S5-10.
6. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis, 2001; 21: 27-41.
7. Pagano G, Pacini G, Musso G et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology, 2002; 35: 367-372.
8. Sligte K, Bourass I, Sels JP, Driessen A, Stockbrügger RW, Koek GH. Non-alcoholic steatohepatitis: review of a growing medical problem. Eur J Intern Med, 2004; 15: 10-21.
9. Marchesini G, Babini M. Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiol, 2006, 54: 229-39.
10. Bahrami H, Daryani NE, Mirmomen S, Kamangar F, Haghpanah B, Djalili M. Clinical and histological features of nonalcoholic steatohepatitis in Iranian patients. BMC Gastroenterol, 2003; 3: 27-33.
11. Zafrani ES. Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virch Arch, 2004; 444: 3-12.
12. Neuschwander-Terti BA, Caldwell SH. Nonalcoholic Steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology, 2003; 37: 1202-1219.
13. Konturek PC, Konturek JW, Cześnikiewicz-Guzik M, Brzozowski T, Sito E, Konturek SJ. Non-hormonal control of food intake: basic mechanisms and clinical implications. J Physiol Pharmacol 2005; 56, Suppl VI: 5-25.
14. Czaja MJ. Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology, 2004; 40: 19-22.
15. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver flbrosis in the severely obese. Gastroenterology, 2001, 121: 91-100.
16. Gabriel A, Ziólkowski A. New terminology of chronic hepatitis, including a scoring scale. Med Sci Monit, 1997; 3: 113-118.
17. Mofrad P, Contos MJ, Haque M et al. Clinical and histological spectrum of non-alcoholic fatty liver disease associated with normal ALT values. Hepatology, 2003; 37: 1286-1292.
18. Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Met, 2002; 16: 703-716.
19. Park KS, Lee YS, Park HW et al. Factors associated or related to with pathological severity of nonalcoholic fatty liver disease. Korean J Intern Med, 2004; 19: 19-26.
20. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol, 2005; 42: 132-138.
21. Godsland IF, Crook D, Proudler AJ, Stevenson JC. Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome. J Clin Endocrinol Metab, 2005; 90: 190-197.
22. Rosito GA, D'Agostino RB, Massaro J et al. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost, 2004; 91: 683-639.
23. Alam AA, Mitwalli AH, Al-Wakeel JS, Chaudhary AR, Zebaid MA. Plasma fibrinogen and its correlates in adult Saudi population. Saudi Med J, 2004; 25: 1593-1602.
24. Lubrano C, Cornoldi A, Pili M et al. Reduction of risk factors for cardiovascular diseases in morbid- obese patients following biliary-intestinal bypass: 3 years follow-up. Int J Obes Relat Metab Disord, 2004; 28: 1600-1606.
25. Svegliati-Baroni G, Ridolfi F, Di Sario A et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology, 1999; 29: 1743-51.
26. Paradis V, Perlemuter G, Bonvoust F et al. High glucose and hyper-insulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology, 2001; 34 (4 Pt 1): 738-44.
27. Spaulding L, Trainer Th, Janiec D. Prevalence on non-alcoholic steatohepatitis in morbidly obese subjects undergoing gastric bypass. Obes Surg, 2003; 13: 347-349.
28. Kral JG, Thung SN, Biron S et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery, 2004; 135: 48-58.
29. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol, 2000; 95: 1370-1371.
30. Marceau P, Biron S, Hould FS et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab, 1999; 84: 1513-1517.
31. Baltasar A, Serra C, Pérez N, Bou R, Bengochea M. Clinical hepatic impairment after the duodenal switch. Obes Surg, 2004; 13: 77-83.
32. Mendler MH, Kanel G, Govindarajan S. Proposal for histological scoring and grading system for non-alcoholic fatty liver disease. Liver Int, 2005; 25: 294-304.
33. Moretto M, Kupski C, Mottin CC et al. Hepatic steatosis in patients undergoing bariatric surgery and its relationship to Body Mass Index and co-morbidities. Obes Surg, 2003; 3: 622-624.
34. Cotrim HP, De-Freitas LA, Freitas C et al. Clinical and histopathological features of NASH in workers exposed to chemicals with or without associated metabolic conditions. Liver Int, 2004; 24: 131-135.
35. Fong DR, Nehra V, Lindor KD, Buchman AL. Metabolic and nutritional considerations in non-alcoholic fatty liver. Hepatology, 2000; 32: 3-10.
36. Papadia FS, Marinari GM, Camerini G et al. Liver damage in severely obese patients: a clinical-biochemical-morphologic study on 1000 liver biopsies. Obes Surg, 2004; 14: 952-958.